Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix
Enrolling by invitationOBSERVATIONAL
Enrollment
20
Participants
Timeline
Start Date
February 1, 2025
Primary Completion Date
December 1, 2027
Study Completion Date
December 1, 2032
Conditions
Cervix CancerCadonilimabSmall Cell Neuroendocrine Carcinoma of the Cervix
Trial Locations (1)
430000
ongji Hospital, Tongji Medical College, Huazhong University of Science andTechnology, Wuhan
All Listed Sponsors
lead
Ding Ma
OTHER
NCT06810895 - Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix | Biotech Hunter | Biotech Hunter